Skip to content

Exercise Intervention for Cancer Patients

Exercise Intervention for Cancer Patients to Increase Physical Activity During Chemotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04151238
Enrollment
8
Registered
2019-11-05
Start date
2020-02-17
Completion date
2020-05-08
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Exhausting chemotherapy, adverse effects of chemotherapy and a lack of information on the benefits of physical exercise are the among the reasons for reduced physical exercise among cancer patients during chemotherapy courses. According to best current knowledge only about 10% of cancer patients in Finland are physically active during cancer treatment. In addition, only 20-30% are physically active after recovery from the treatments (Pylkkänen, 2015). There is only little awareness about the benefits of physical activity during cancer treatments. The purpose of the exercise intervention study is to increase the physical activity of patients who are on chemotherapy. The study is a pilot trial and has no control group. Internationally, exercise interventions have been studied among cancer patients on treatment for decades. The American College of Sports Medicine (ACSM) recommends that cancer patients should have 150 minutes of endurance exercise per week and at least two bouts of muscle strength exercise per week. Consequently, the exercise intervention study will have a combination of muscle power and endurance training. To reach the weekly recommended level of exercise, the cancer patients in the study will additionally have a weekly home training program containing preferentially endurance training. A literature search shows that no studies on exercise interventions during cancer treatment have been published in Finland. Thus, this thesis carries the wider implication of increasing the general knowledge on the importance of physical activity of cancer patients.

Detailed description

The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary. Before the intervention is started, an oncologist will examine the participants condition before brisk physical activity is started. Safety is an important consideration and a nurse will examine the patients before each bout of exercise. A nurse will be present during the entire time of the exercise. A physician is always available for consultations by phone. Before the intervention starts, baseline measurements will be made in the laboratories of physical exercise in the Tyks Hospital and the Turku University of Applied Sciences. At baseline, endurance, muscle power, balance and body composition will be evaluated and recorded. Endurance will be measured with a submaximal treadmill test. Muscle power will be assessed by a dynamic elevation test, hand pressure test, the lower extremities by repeated squatting-standing and by rising to stand on the toes. Balance is measured in the specific sway platform (one leg and both legs standing). The patients will be asked to fill questionnaires on quality of life (QLQ-c30) and fatigue (FACIT-F) before and after the intervention. The patients will fill in their exercise diaries from the very moment their participation has been decided until the end of the intervention. After exercise intervention the patients also fill the feedback-questionnaire.

Interventions

BEHAVIORALExercise intervention for cancer patients to increase physical activity during chemotherapy

The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.

Sponsors

Turku AMK Master School
CollaboratorUNKNOWN
Turku University Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* cancer patients in the age of 18-70 * in the early phase of chemotherapy * first line chemotherapy * active way of treating cancer * solid tumor (breast cancer, prostata cancer, colon cancer and melanoma) * Finnish-speaking * z=0-1 (no aids) * capable travelling to University hospital for 8 weeks twice a week * normal or poor physical activity background

Exclusion criteria

* exercise contraindications, like severe respiratory or circulatory system disease (eg. heart attack \<3) * brain or bone metastasis * heterogenous group (max 4 patients per cancer diagnose) * thrombocytopenia * leukocytopenia * immuno-oncological treatments * really athlete patients

Design outcomes

Primary

MeasureTime frameDescription
physical activity changes in diary0 and 8 weeks,Does this exercise intervention model works for cancer patients to increase the amount of physical activity and to achieve the cancer patients exercise recommendations? (especially home-exercising)
questionnaire-feedback from cancer patients0 and 8 weeksDoes this exercise intervention model works for cancer patients to change the amount of physical activity? Patients subjective feedback about the first exercise group model in special health care. The questions are formed in quantitative way.

Secondary

MeasureTime frameDescription
Body composition in cancer patients general view (In-Body-device)0 and 8 weeksDoes exercise intervention (physical activity) cause changes in the body composition of cancer patients on chemotherapy? The device measures body mass index, fluid, fat and muscle changes. We follow up the changes in general view.
Endurance (submaximal treadmill test)0 and 8 weeksDoes exercise intervention (physical activity) cause changes in endurance of cancer patients on chemotherapy?
Functional muscle power test - dynamic elevation test for upper arms0 and 8 weeksDoes exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy?
Functional muscle power test - hand pressure test0 and 8 weeksDoes exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy?
Quality of life questionnaire (EORTC QLQ-c30)0 and 8 weeksDoes the guided exercise intervention (physical activity) affect the patients quality of life during chemotherapy? The scales and single-item measures range in score from 0 to 100. High score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. The scale consists of three different part.
Functional muscle power test - the lower extremities by rising to stand on the toes0 and 8 weeksDoes exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy?
Functional muscle power test - plank-test for the body0 and 8 weeksDoes exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy?
Balance -tests in specific sway-platform (standing with both legs and only one leg in sway-platform)0 and 8 weeksDoes exercise intervention (physical activity) cause changes in the balance of cancer patients on chemotherapy?
Functional muscle power test - the lower extremities by repeated squatting-standing0 and 8 weeksDoes exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy?
Fatigue questionnaire (FACIT-F)0 and 8 weeksDoes the guided exercise intervention (physical activity) affect the patients fatigue during chemotherapy? The score range: 0-52 points. The bigger points the worse fatigue or more symptoms.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026